Skip to main content

Advertisement

SpringerLink
Log in

Testosterone Replacement Therapy and Prostate Health

  • Benign Prostatic Hyperplasia (K McVary, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

There is an emerging evolution in the understanding of the relationship between the prostate and testosterone. It has long been generally believed that with testosterone replacement therapy (TRT), increasing serum testosterone levels led to prostatic growth and worsening of voiding dysfunction and associated complications. A new theory, the Saturation Model of Testosterone and its effect on the Prostate has gained attention. This theory suggests that the prostate’s response to increasing levels of serum testosterone reaches a limit beyond which there is minimal effect. This model predicts that testosterone replacement therapy occurs above this saturation point, and replacing testosterone to eugonadal levels should not worsen prostate related benign disease. We evaluated the recent published data, with an emphasis on clinical studies done within the last 3 years, for the effects of testosterone supplementation on benign prostatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. J Clin Endocrinol Metab. 2001;86(2):724–31.

    Article  PubMed  CAS  Google Scholar 

  2. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589–98.

    Article  PubMed  CAS  Google Scholar 

  3. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metabol. 2004;89:5920–6.

    Article  CAS  Google Scholar 

  4. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–98.

    Article  PubMed  CAS  Google Scholar 

  5. •• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–7. While not focused on benign disease, this discovery won the Nobel Prize in Medicine and established the link between testosterone and prostate cancer growth.

    CAS  Google Scholar 

  6. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls Clin. Endocrinol. 1994;40:341–6.

    CAS  Google Scholar 

  7. Meikle WA, Stephenson RA, Lewis CM. Middleton Effects of age and sex hormones on transition and peripheral zone volumes in benignprostatic hyperplasia in twins J. Clin Endocrinol Metab. 1997;82:571–5.

    Article  CAS  Google Scholar 

  8. •• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75. This recent meta-analysis provides an overview of adverse effects of testosterone replacement therapy.

    Article  PubMed  Google Scholar 

  9. • Nickel JC. Comparison of Clinical Trials With Finasteride and Dutasteride. Rev Urol. 2004;6 Suppl 9:S31–9. This review provides comparison trials of Finasteride and Dutasteride.

    PubMed  Google Scholar 

  10. •• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310–20. Epub 2008 Sep 24. This paper provides an overview of the Saturation Model of Testosterone and the Prostate.

    Article  PubMed  Google Scholar 

  11. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168(12):1416–24. Epub 2008 Oct 21.

    Article  PubMed  Google Scholar 

  12. Goldenberg SL, Koupparis A, Robinson ME. Differing levels of testosterone and the prostate: a physiological interplay. Nat Rev Urol. 2011;8(7):365–77.

    Article  PubMed  CAS  Google Scholar 

  13. •• Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61. Well designed RCT that evaluates the effects of Serum testosterone and intraprostatic levels, gene expression and prostate growth.

    Article  PubMed  CAS  Google Scholar 

  14. Page ST, Lin DW, Mostaghel EA, et al. Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized –Controlled Trial. J Clin Endocrinol Metab. 2011;96(2):430–7.

    Article  PubMed  CAS  Google Scholar 

  15. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24(3):299–311.

    PubMed  Google Scholar 

  16. • Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005–11. Epub 2011 Jul 23. Evaluates the effect of TRT and PSA over a year, and the changes during that year.

    Article  PubMed  CAS  Google Scholar 

  17. Coward RM, Simhan J, Carson 3rd CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009;103(9):1179–83. Epub 2008 Dec 23.

    Article  PubMed  CAS  Google Scholar 

  18. Rhoden EL, Morgentaler A. influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006;18:201–5.

    Article  PubMed  CAS  Google Scholar 

  19. Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG. Lower Urinary Tract Symptoms Revisited: A Broader Clinical Perspective. Eur Urol. 2008;54(3):563–9.

    Article  PubMed  Google Scholar 

  20. • Shigehara K, Sugimoto K, Konaka H, et al. Androgen Replacement Therapy Contributes to Improving Lower Urinary Tract Symptoms in Patients with Hypogonadism and Benign Prostate Hypertrophy: a randomized controlled study. Aging Male. 2011;14(1):53–8. RCT examining the relationship between treatment of LOH and LUTS.

    Article  PubMed  Google Scholar 

  21. Favilla V, Cimino S, Castelli T, et al. Relationship Between Lower Urinary Tract Symptoms and Serum Levels of Sex Hormones in Men with Symptomatic Benign Prostatic Hyperplasia. BJUI. 2010;106:1700–3.

    Article  Google Scholar 

  22. Liao CH, Chiang HS, Yu HJ. Serum Testosterone Levels Significantly Correlate with Nocturia in Men Aged 40-79 Years. J Urol. 2011;78(3):631–5.

    Article  Google Scholar 

  23. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554–9.

    Article  PubMed  CAS  Google Scholar 

  24. Takao T, Tsujimura A, Nakayama J, et al. Lower Urinary Tract Symptoms After Hormone Replacement Therapy in Japanese Patients with Late-onset Hypogonadism: A Preliminary Report. Int J Urol. 2009;16:212–4.

    Article  PubMed  Google Scholar 

  25. Haider H, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41(1):7–13.

    Article  PubMed  CAS  Google Scholar 

  26. Amano T, Imao T, Takemae K, et al. Testosterone Replacement Therapy by Testosterone Ointment Relieves Lower Urinary Tract Symptoms in Late Onset Hypogonadism Patients. Aging Male. 2010;13(4):242–6.

    Article  PubMed  CAS  Google Scholar 

  27. • Zhang Y, Chen J, Hu L, et al. Androgen Deprivation Induces Bladder Histological Abnormalities and Dysfunction via TGF-beta in Orchiectomized Mature Rats. Tohoku J Exp Med. 2012;226:121–8. Basic science paper that provides a histological explanation for findings of improvement of LUTS with TRT.

    Article  PubMed  CAS  Google Scholar 

  28. • Gacci M, Corona G, Salvi M, et al. A Systematic Review and Meta-Analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with Alpha-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. EAU. 2012;61:994–1003. Recent meta-analysis demonstrating the superiority of dual agent therapy.

    CAS  Google Scholar 

  29. Kruep EJ, Hogue SL, Eaddy MT, Chandra MD. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. P T. 2011;36(8):493–507.

    PubMed  Google Scholar 

  30. Idan A, Griffiths KA, Harwood DT, et al. Long-Term Effects of Dihydrotestosterone Treatment on Prostate Growth in Healthy, Middle-Ages Men Without Prostate Disease. Ann Intern Med. 2010;153:621–32.

    PubMed  Google Scholar 

  31. Marberger M, Roehrborn CG, Marks LS, et al. Relationship among Serum Testosterone, Sexual Function, and the Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia. J Clin Endocrinol Metab. 2006;91(4):1323–8.

    Article  PubMed  CAS  Google Scholar 

  32. • Page ST, Hirano L, Gilchriest J, et al. Dutasteride Reduces Prostate Size and Prostate Specific Antigen in Older Hypogonadal Men With Benign Prostatic Hyperplasia Undergoing Testosterone Replacement Therapy. J Urol. 2011;186:191–7. RCT demonstrating TRT does not interfere with the action of 5ARIs.

    Article  PubMed  CAS  Google Scholar 

  33. Hong, Sung Kyu. Min, Gyeong Eun. Ha, Seung Bum, et al.: Effect of the dual 5-alpha- reductase inhibitor, dutasteride, on serum testosterone and body mass index in med with benign prostatic hyperplasia. BJUI 2009 105, 970-97.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Urology, Oregon Health & Science University, 3303 SW Bond Ave CH10U, Portland, OR, 97239, USA

    A. Scott Polackwich, Kevin A. Ostrowski & Jason C. Hedges

Authors
  1. A. Scott Polackwich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin A. Ostrowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason C. Hedges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason C. Hedges.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Polackwich, A.S., Ostrowski, K.A. & Hedges, J.C. Testosterone Replacement Therapy and Prostate Health. Curr Urol Rep 13, 441–446 (2012). https://doi.org/10.1007/s11934-012-0275-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-012-0275-8

Keywords

Search

Navigation